Hedrick Marc H.'s most recent trade in Plus Therapeutics Inc was a trade of 8,066 Common Stock done . Disclosure was reported to the exchange on July 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 8,066 | 42,497 (1%) | 0% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 8,066 | 155,584 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 6,387 | 34,431 (0%) | 0% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 6,387 | 163,650 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 1,986 | 44,483 (1%) | 0% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2026 | 1,986 | 153,598 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 23,834 | 170,037 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 23,834 | 23,834 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 201,632 | 3,655,075 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 201,632 | 701,100 (18%) | 5% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 159,681 | 499,468 (13%) | 4% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 159,681 | 3,856,707 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 2,419,582 | 4,016,388 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2026 | 2,419,582 | 2,419,582 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2026 | 159,681 | 339,787 (9%) | 4% | 0 | Common Stock | |
| Plus Therapeutics Inc | Hedrick Marc H. | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2026 | 159,681 | 1,596,806 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 159,681 | 180,106 (4%) | 4% | 0 | Common Stock | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2025 | 159,681 | 1,756,487 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 5,748,506 | 5,748,506 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 5,748,506 | 5,748,506 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 1,916,168 | 1,916,168 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2025 | 1,916,168 | 1,916,168 | - | - | Restricted Stock Units | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 400,489 | 400,489 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2024 | 197,595 | 197,595 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.23 per share. | 10 Sep 2024 | 8,000 | 20,425 (0%) | 0% | 1.2 | 9,839 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 24,510 | 24,510 | - | - | Warrants (Right to buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 08 May 2024 | 12,255 | 12,425 (0%) | 0% | 2.0 | 25,000 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 94,012 | 94,012 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Hedrick Marc H. | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 1.96 per share. | 20 Nov 2023 | 2,068 | 170 (0%) | 0% | 2.0 | 4,053 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 483,824 | 483,824 | - | - | Stock Option (Right to Buy) | |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.65 per share. | 15 Jun 2022 | 5,000 | 33,580 (0%) | 0% | 0.6 | 3,240 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 27 Apr 2022 | 2,500 | 28,580 (0%) | 0% | 0.7 | 1,710 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 0.69 per share. | 26 Apr 2022 | 5,000 | 26,080 (0%) | 0% | 0.7 | 3,450 | Common Stock |
| Plus Therapeutics Inc | Marc H. Hedrick | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.66 per share. | 26 Oct 2021 | 2,500 | 21,080 (0%) | 0% | 1.7 | 4,150 | Common Stock |